Gang Li

Dr. Gang Li


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2024 in The FASEB Journal
Verified
Journal Article
Closed access
DWDan Wang
Dan Wang
JZJing Zhang
Jing Zhang
HYHouqing Yin
Houqing Yin
RYRibai Yan
Ribai Yan
ZWZequn Wang
Zequn Wang
YPYan Pan
Yan Pan

1 January 2023
Verified
Journal Article
Closed access
SRSiqian Ren
Siqian Ren
ASAbuduhaibaier Sadula
Abuduhaibaier Sadula
CYChen Ye
Chen Ye
QCQing Chen
Qing Chen
MYMeng Yuan
Meng Yuan
AYAnd Chunhui Yuan
And Chunhui Yuan

7 July 2020 in BMJ Open
Verified
Journal Article
Open access
PDF file
GLGang Li
Gang Li
YXYongxing Xu
Yongxing Xu
YYYitian Yang
Yitian Yang
PLPengfei Liu
Pengfei Liu
Introduction: COVID-19 has spread rapidly in China and around the world. Published studies have revealed that some patients with COVID-19 had abnormal liver function in laboratory tests. However, the results were inconsistent and the analysis of epidemiological data stratified by the severity of COVID-19 was not available in previous meta-analyses. Furthermore, these meta-analyses were suspected of overestimating the incidence of liver injury in patients with COVID-19 because some studies considered transaminase elevation as liver injury, which might partially result from cardiac and muscle injury. This systematic review aims to enrol published literatures related to COVID-19 without language restriction, analyse the data based on the severity of the COVID-19 and explore the impact of varied definitions of liver injury on the incidence of liver injury.Methods and analysis: We have conducted a preliminary search on PubMed and Excerpta Medica Database on 13 April 2020, for the studies published after December 2019 on the prevalence of acute liver injury and hypertransaminemia in patients with COVID-19. Two reviewers will independently screen studies, extract data and assess the risk of bias. We will estimate the pooled incidence of hypertransaminemia and acute liver injury in patients with COVID-19 by using the random-effects model. The I² test will be used to identify the extent of heterogeneity. Publication bias will be assessed by funnel plot and performing the Begg’s and Egger’s test if adequate studies are available. We will perform a risk of bias assessment using the Joanna Briggs Institute’s critical appraisal checklist.Ethics and dissemination: Since this study will be based on the published data, it does not require ethical approval. The final results of this study will be published in a peer-reviewed journal.PROSPERO registration number: CRD42020179462.